News

Fresh funding backs a high-stakes attempt to do what current amyloidosis drugs still cannot: clear the buildup already damaging the heart.UK-based biotech Immutrin…

The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge…

Amyloidosis is a rare disease involving the formation and spread of abnormal proteins in the body. Unlike with other proteins, the body cannot naturally recycle…

PurposeAmyloid positron emission tomography (PET) tracers are increasingly used to detect cardiac amyloidosis (CA). 11C-Pittsburgh compound B (PiB) and 1⁸F-…

The partnership will see Viz.ai develop an AI Care Pathway for cardiac amyloidosis.Viz.ai has entered a collaboration with Alnylam to advance earlier identification…

Viz.ai has announced a partnership with Alnylam Pharmaceuticals to improve early identification and care coordination for patients with cardiac amyloidosis, a…

Join the CCS for the third and final installment of the Amyloid Education Series 2.0 in the upcoming webinar, ‘Cases and Clinical Conundrums in Amyloidosis…

The WashU Medicine Amyloid Center of Excellence has been selected as one of just 10 centers nationwide to participate in the American Heart Association’s ATTR-CM…

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals (NASDAQ:ALNY) announced Tuesday partnerships with Viz.ai and the American Heart Association aimed at improving early…

Alnylam Pharmaceuticals highlighted the early commercial success of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy during a recent webinar. The company reported a…